Anosmia 1 Year After a COVID-19 Diagnosis

The number of people with post-COVID-19 syndrome seems to be growing exponentially, so we need long-term data to help physicians advise patients correctly.

Anosmia a un año del diagnóstico de COVID-19

Among the many persistent symptoms, post-COVID-19 anosmia has good prognosis and almost full recovery at 1 year.

In April, 2020, these same authors published a cohort of almost 100 COVID-19 positive patients (positive PCR) with acute smell loss beyond 7 days.

During the 1-year follow-up, patients were asked to complete a survey regarding their olfactory function every 4 months.

Hyposmic or anosmic patients were followed until objective olfactory recovery.

About half of them were evaluated using subjective and objective olfactory tests. The other half underwent subjective assessment alone.

After the first assessment, at 4 months, 45.1% of patients reported full recovery of olfaction, 52.9% reported partial recovery, and 2% reported no recovery.


Read also: Discrepancy between Angina and Ischemia Repeats in Peripheral Artery Disease.


In the group that was able to undergo a test to objectify olfactory function, 84.3% showed a normal result—although 70% of patients stated that they had only partially recovered their sense of smell.

The remaining 15.7% showed abnormal subjective and objective tests, and these patients were re-evaluated at 8 months.

After 4 months, objective tests confirmed full recovery in almost all patients.


Read also: Could Statins Do More than Lower Cholesterol in COVID-19 Patients?


Only 2 patients continued with abnormal tests at 1 year: one patient with decreased olfaction and one with parosmia (abnormal smell identification).

Conclusion

COVID-19 related persistent anosmia has great prognosis and is almost fully resolved after one year.

post-COVID-anosmia

Original Title: Clinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis.

Reference: Marion Renaud et al. JAMA Network Open. 2021;4(6):e2115352. doi:10.1001/jamanetworkopen.2021.15352.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is the Booster Dose Against COVID-19 Effective for All Ages?

The answer is incontrovertible: it is undeniably effective. For all ages, the confirmed COVID19 and severe case rates were significantly lower for patients who...

Pfizer Booster Dose Efficacy against Omicron

The BNT162b2 vaccine (Pfizer/BioNTech) has previously shown a 95% efficacy against COVID-19. This efficacy has been changing with the surge of new variants and,...

Once Again, the Omicron Variant Tests the Limits of Healthcare Systems, But with Hope

The latest significant COVID-19 variant, the Omicron, is again pushing healthcare systems around the world onto the verge of collapse, having reached over 300...

The Most Read Articles of 2021: COVID-19

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on COVID-19. Follow...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....